Apr, 1 2026, 5 Comments
Understanding how biosimilar safety is tracked through adverse event monitoring systems, including differences from generic drugs and current global regulatory frameworks.
Read More
Feb, 2 2026, 10 Comments
Generic drugs are set to dominate global healthcare as patent expirations surge, driving down costs and expanding access. Forecasts show the market could hit $700B+ by 2030, led by biosimilars, Asia-Pacific growth, and complex drug manufacturing advances.
Read More